OR WAIT null SECS
© 2025 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.
Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 pharmaceutical firms, and various other life sciences stakeholders.
Chrysalis, a good manufacturing practice (GMP)-ready space and service provider with facilities in Massachusetts and North Carolina, has officially launched following a strategic ownership investment and the acquisition of facility assets from Azzur Group, a press release from the new company said on June 16, 2025 (1).
The acquired assets provide the company with GMP-compliant cleanroom spaces that Chrysalis said will be flexible and able to be tailored to life science innovators and biopharmaceutical companies, with entry times as short as four to six weeks (1). As the companies work to clear key milestones to get transformative therapies to clinic, Chrysalis’ involvement permits these innovators to retain full ownership of their programs so that they can meet individual timelines and technical requirements.
“Our model is particularly valuable for programs where retaining process control, protecting IP [intellectual property], and minimizing risk are crucial considerations,” said Sarah Stevens, Chrysalis CEO, in the press release (1). “Our approach gives our customers flexibility to take only the space and services they need, when they need it. By providing rapid access to GMP-compliant space and operational support, we empower our customers to advance on their own terms, transforming scientific promise into real progress without the burden of scheduling constraints or unnecessary ongoing expense.”
In the press release, Chrysalis listed among its partners early-stage biotechnology companies, contract research organizations, top-10 pharmaceutical firms, and various other life sciences stakeholders (1). The company’s facilities are intended to accommodate a range of needs and therapeutic modalities.
“Whether clients are navigating early development or preparing for commercialization, we’re here to grow with them,” Stevens said (1). “We don’t just provide space, we build partnerships grounded in collaborative operational excellence and a deep understanding of what it takes to operate in a GMP environment.”
The May 2025 issue of Pharmaceutical Technology® examined the evolution of cleanroom procedures in the context of a shift in the market toward personalized medicines, listing the challenges in maintaining sterile environments (2).
“The evolving regulatory requirements over the years as well as the increasing biopharmaceutical complexity and growing demand for aseptic processing have prompted significant advancements in cleanroom technologies and analytical testing methods,” the article says (2). “These innovations have been driven by the need for faster, more accurate contamination detection, improved environmental monitoring, and greater flexibility in biomanufacturing. Innovations include rapid microbiological methods, next-generation sequencing, real-time environmental monitoring, and the use of digitalization and artificial intelligence in cleanroom analytics.”
Chrysalis said it plans to scale rapidly following its launch, enhancing infrastructure and expanding into other geographical areas (1).
1. Chrysalis. Chrysalis Launches with Acquired Cleanroom Assets to Deliver Flexible Manufacturing Solutions. Press Release. June 16, 2025.
2. Mirasol, F. Evolving Cleanroom Procedures and Sterility Challenges. Pharmaceutical Technology 2025, 49 (4) 28–29.
